Q-omics provides the consensus-scored DNM3OS profile across patient tissues and cancer cell-line models. DNM3OS expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DNM3OS is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, DNM3OS RNA expression shows 19,306 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where DNM3OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM3OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM3OS survival associations across molecular data types. DNM3OS RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM3OS RNA expression–survival associations across cancer types. High DNM3OS expression shows unfavorable associations in KIRP, UVM, LGG, ACC and GBM, but favorable associations in UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DNM3OS RNA expression.
This table summarizes DNM3OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNM3OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM3OS shows lower tumor expression in KIRC, KICH, KIRP, UCEC, LUSC and LIHC. The KIRC box plot shows higher DNM3OS RNA expression in normal versus tumor tissue (log2 FC = −0.574, t-test p < 0.001).
This table shows molecular features associated with DNM3OS in patient tissues and cancer cell lines. In patient samples, DNM3OS shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
